The Cardiomyopathy drugs in development market research report provides comprehensive information on the therapeutics under development for Cardiomyopathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Cardiomyopathy. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Cardiomyopathy and features dormant and discontinued products.
GlobalData tracks 117 drugs in development for Cardiomyopathy by 76 companies/universities/institutes. The top development phase for Cardiomyopathy is preclinical with 53 drugs in that stage. The Cardiomyopathy pipeline has 111 drugs in development by companies and six by universities/ institutes. Some of the companies in the Cardiomyopathy pipeline products market are: DiNAQOR, Tenaya Therapeutics and Bristol-Myers Squibb.
The key targets in the Cardiomyopathy pipeline products market include Myosin, Plakophilin 2 (PKP2), and BAG Family Molecular Chaperone Regulator 3 (Bcl 2 Associated Athanogene 3 or Bcl 2 Binding Protein Bis or Docking Protein CAIR 1 or BAG3).
The key mechanisms of action in the Cardiomyopathy pipeline product include Myosin Inhibitor with five drugs in Phase III. The Cardiomyopathy pipeline products include 13 routes of administration with the top ROA being Oral and 12 key molecule types in the Cardiomyopathy pipeline products market including Gene Therapy, and Small Molecule.
Cardiomyopathy overview
Cardiomyopathy a disease of the heart muscle, where the walls of the heart chambers have become stretched, thickened or stiff. This affects the heart’s ability to pump blood around the body. Most types of cardiomyopathy are inherited. It can also be caused by other conditions, or risk factors, but for some people the cause is unknown. Cardiomyopathy can affect people of all ages
For a complete picture of Cardiomyopathy’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
